Skip to content
GLP-1 Desk
Menu
Dispatch #398

ElleS

ElleS (ElleS Inc.) is a comprehensive compounded telehealth service.

Visit ElleSAssume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we file on a provider reads the same either way.
Semaglutide
Not disclosed
Tirzepatide
Not disclosed
Coverage
Coverage not published
Brand-name
Compounded only

Line ElleS up against its closest alternatives. Or go one-on-one: ElleS vs CoreAge Rx. Because ElleS dispenses compounded medication, it’s worth understanding whether compounded GLP-1 is legit and safe.

Desk Score breakdown

Each of the six scored dimensions. See the methodology.

Price transparency44/100
State access24/100
Molecule range51/100
Onboarding speed68/100
Support responsiveness79/100
Licensing & trust71/100

What the Desk likes

  • Compounded semaglutide and tirzepatide in both injectable and oral-capsule forms, plus microdose options
  • Packages bundle the telehealth visit, medication, and shipping; Registered Dietitian support included
  • Full legal suite published — Terms, Privacy Policy, Privacy Practices, and Medical Consent
  • Broad menu: also TRT, HRT (estradiol), sexual health, hair loss, and longevity (sermorelin, NAD+)

Where points come off

  • Pricing not shown publicly — products and costs appear only after the intake flow
  • Sold as 3- and 6-month packages rather than simple monthly plans
  • Compounding pharmacy partner not named ('made in licensed US facilities')
  • Not LegitScript-certified (no certification displayed)

The Desk's briefing — C

Best for: Shoppers wanting compounded GLP-1 (including oral capsules) within a broad telehealth menu.

ElleS ranks #398 of 498 providers scored — see #1, CoreAge Rx on the board.

Related dispatches

Everyone else on the board (18)

Pricing and verification reflect ElleS's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on ElleS's site. Not medical advice; see our disclosure.

← Back to The Desk